Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol IL1R2 contributors: mct/npt - updated : 29-05-2010
HGNC name interleukin 1 receptor, type II
HGNC id 5994
EXPRESSION
Type
   expressed in (based on citations)
organ(s)
cells
SystemCellPubmedSpeciesStageRna symbol
Lymphoid/ImmuneB cell
Lymphoid/ImmuneT cell
cell lineage
cell lines
fluid/secretion
at STAGE
PROTEIN
PHYSICAL PROPERTIES
STRUCTURE
motifs/domains
  • a ligand binding domain
  • three Ig-like domain
  • a single transmembrane domain
  • a short cytoplasmic domain lacking the Drosophila Toll signal (see IL1R1)
    • isoforms Precursor with a transmembrane isoform and an alternatively spliced soluble form (secreted)
    HOMOLOGY
    Homologene
    FAMILY
  • interleukin-1 receptor family
    • CATEGORY signaling cytokine , receptor
    SUBCELLULAR LOCALIZATION     plasma membrane
    text transmembrane protein
    basic FUNCTION
  • molecular decoy that traps interleukin-1beta (IL1B) and does not initiate subsequent signaling events, thereby suppressing an inflammatory response (Vambutas 2009)
    • CELLULAR PROCESS
    PHYSIOLOGICAL PROCESS
    PATHWAY
    metabolism
    signaling
    a component
    INTERACTION
    DNA
    RNA
    small molecule
    protein
    cell & other
    REGULATION
    induced by by dexamethasone (Vambutas 2009)
    ASSOCIATED DISORDERS
    corresponding disease(s)
    Other morbid association(s)
    TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
    constitutional     --over  
    appears to be a protective mechanism in hearing homeostasis (Vambutas 2009)
    constitutional     --over  
    results in changes in cell morphology, actin rearrangement, and promoted cell migration, through activation of the pre-interleukin 1alpha pathway (Chang 2009)
    Susceptibility to ankylosing spondylitis
    Variant & Polymorphism
    Candidate gene may be a specific biomarker for Autoimmune Inner Ear Disease (AIED) (Vambutas 2009)
    Marker
    Therapy target can neutralize IL1 beta and counteract its effect on endometrial stromal cells, and may provide a new clinical strategy for the treatment of endometriosis (Hou 2008)
    ANIMAL & CELL MODELS